Drug Interaction of O-Tinib 100mg Capsule
Dihydroergotamine + Imatinib
The use of this is contraindicated because the use of Imatinib will increase the effect of dihydroergotamine by affecting patient hepatic and intestinal enzyme metabolism.
Deferiprone + Imatinib
Use alternative drug because the combination of this medicine either increase the toxicity of the other by pharmacodynamic synergism
Erdafitinib + Imatinib
Use alternative drugs because the use of erdafitinib will increase the effect of imatinib by P-glycoprotein efflux transporter.
Acetaminophen + Imatinib
Therapy should be administered with caution because the use of imatinib decreases the effect of acetaminophen by decreasing its hepatic clearance
The use of grapefruit juice increases the blood level of imatinib and also increases the risk of side effects such as dizziness, confusion, hallucinations, mood changes, insomnia, drowsiness, congestive heart failure, and QT prolongation.
Therapy should be administered with caution because the use of multiple kinase inhibitors causes arterial vascular occlusive events, peripheral arterial occlusive events, and ischemic cerebrovascular events.
Therapy should be administered with caution in patients who are having fluid retention because the use of multiple tyrosine kinase inhibitors may cause pericardial effusion, pleural effusion, pulmonary edema, and peripheral edema.
Bone marrow suppression:
Therapy should be administered with caution in patients with bone marrow suppression because the use of multiple tyrosine kinase inhibitors may cause thrombocytopenia, aplastic anemia, agranulocytosis, and neutropenia.
Therapy should be administered with caution in patients with hepatic impairment. Monitor the patient hepatic function during the treatment.